1. Periocular Epithelioid Hemangioma: Response to Bevacizumab and Vascular Pathogenesis
- Author
-
Victor M. Elner, Alon Kahana, Brian J. Lee, and Andrew Flint
- Subjects
Vascular Endothelial Growth Factor A ,Pathology ,medicine.medical_specialty ,genetic structures ,Bevacizumab ,Angiogenesis Inhibitors ,Injections, Intralesional ,Antibodies, Monoclonal, Humanized ,Article ,Benign tumor ,Pathogenesis ,Young Adult ,Orbital Diseases ,medicine ,Humans ,Angiolymphoid hyperplasia with eosinophilia ,Epithelioid Hemangioma ,Retrospective Studies ,Peripheral Vascular Diseases ,business.industry ,Angiolymphoid Hyperplasia with Eosinophilia ,medicine.disease ,Debulking ,Magnetic Resonance Imaging ,eye diseases ,body regions ,Ophthalmology ,medicine.anatomical_structure ,Debridement ,Eyelid Diseases ,Blood Vessels ,Female ,Kimura Disease ,sense organs ,Tomography, X-Ray Computed ,business ,Orbit (anatomy) ,medicine.drug - Abstract
Epithelioid hemangioma (EH), also known as angiolymphoid hyperplasia with eosinophilia, may affect the eyelids and orbit, mimic idiopathic orbital inflammation, and respond poorly to corticosteroids.1,2 We describe a patient with chronic, bilateral orbital EH unresponsive to corticosteroids. Histopathologic analysis showed lobular vascular proliferations containing plump endothelial cells with surrounding mixed leukocytic infiltrates diagnostic of EH.3 Successful treatment consisted of surgical debulking and intralesional bevacizumab. Periocular EH lesions of 2 additional patients treated by debulking also showed prominent lobular vascular proliferations, highlighting them as the basis of this benign tumor. We conclude that EH is primarily a vascular tumor that can respond to bevacizumab.
- Published
- 2012
- Full Text
- View/download PDF